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Chemotactic Factor Inactivator 
in Sera of Sarcoid Patients 
(May 1976) 
Joan Kubik, B.A., American International College 
Directed by: Dr. Warren Litsky 
ABSTRACT 
Sera from eleven untreated patients diagnosed by x-ray 
and biopsy as having sarcoidosis consistent with Stage II 
of the disease (hilar adenopathy with pulmonary infiltrates) 
and thirteen appropriately diagnosed patients without 
staging or regard to current therapy were found to contain 
supernormal levels of chemotactic factor inactivator (CFI). 
The serum inactivator irreversibly inhibited migration by 
normal indicator polymorphonuclear leukocytes toward a 
variety of chemotactic factors both complement independent 
(bacterial factor) and complement dependent (C^ and C^ frag¬ 
ments) in a chemotaxis assay system. 
In the untreated Stage II group of sera, 8 of 11 showed 
477o inhibition t 12 (p 0.001). In the mixed group, all 13 
sera showed greater than 50% inhibition t 10 (p 0.001). 
Stage II sera exhibit selective inactivation of the 
Vll 
C3 fragment in comparison to normal controls. Ultracentrifu¬ 
gal characterization by sucrose density gradient revealed a 
biphasic inactivator pattern not distinguishable from that 
of CFI found in normal human serum. CFI activity was heat 
labile in both sarcoid and normal sera. CFI inactivated the 
chemotactic factors directly. Tests for cell-mediated action 
of the inactivator were inconclusive but indicate in some 
cases cell mediation may occur either inhibiting or enhancing 
cell migration. 
Zymosan activation of most sarcoid sera showed normal 
generation of complement-dependent chemotactic factors via 
the alternate pathway. This result indicated that sarcoid 
sera are not deficient in the third through ninth component 
of complement. 
When miscellaneous normal and pathological sera were 
tested for abnormal CFI levels, it was found that cirrhotics 
and patients with Hodgkin's disease possessed elevated 
levels of inactivator activity. Cancer patients showed 
mixed results in which the CFI levels did not coincide with 
the severity of the patient's immediate condition. These 
patients were all undergoing therapy of various kinds. 
Staging of a disease like sarcoidosis seems to be 
Vlll 
necessary if chemical indicators such as CFI are to be 
assayed in order to assess disease process and progression 
and attention must be paid to current therapy as CFI may 
be very sensitive to various drugs. 
CFI may turn out to be a general and very sensitive 
indicator of pathological conditions occurring in the 
body and its assessment in a wide variety of disease states 
may be an important tool to aid in the diagnosis and 
treatment of many human ailments. 
ix 
TABLE OF CONTENTS 
Page 
INTRODUCTION . 1 
LITERATURE REVIEW. 7 
MATERIALS AND METHODS. 17 
Human era. 17 
Patient Sera. 17 
Normal Human Sera. 17 
Miscellaneous Sera. 17 
Chemotactic Assays. 18 
Indicator Cells . 18 
Assay Procedures. 18 
Chemotactic Factors  29 
Zymosan Activation of Serum Complement. 30 
Assay for Chemotactic Factor Inactivator. 30 
Assay for Cell-Directed Mediators . 31 
Assay for Relative Complement Levels. 32 
Ultracentrifugal Studies. 32 
Calculations. 32 
RESULTS. 34 
Chemotactic Factor Inactivator in NHS . 34 
X 
Page 
CFI in Sera of Patients with Sarcoidosis. 41 
CFI in Group I Sera. 44 
CFI in Group II Sera. 44 
Specificity of the CFI. 45 
Zymosan Studies . 48 
Heat Inactivation Studies . 48 
Cell-Directed Mediator. 50 
Miscellaneous Studies  52 
Cirrhotic Liver Disease. 52 
Hodgkin's Disease. 57 
Cancer. 57 
Prenatal Normal. 57 
High White Count.. . 57 
Physical-Chemical Features of CFI . 58 
DISCUSSION. 61 
APPENDIXES. 73 
A - Staging of Sarcoidosis. 74 
B - Diagnostic Criteria . 75 
C - The Ouchterlony Test. 76 
LITERATURE CITED 77 
xi 
LIST OF TABLES 
Table Page 
I Inactivation of chemotactic factors by- 
normal human sera. 35 
II Effect of heat on inactivator activity of 
normal human sera. 39 
III Bacterial factor inactivator in Group I 
sarcoid se a. 42 
IV Bacterial factor inactivator in Group II 
sarcoid se a. 43 
V Specificity of chemotactic factor inactivator 
in Group I sarcoid ser . 46 
VI Specificity of chemotactic factor inactivator 
in Group II sarcoid sera. 47 
VII Heat lability of serum chemotactic factor 
inactivator. 51 
VIII Effects of sarcoid sera on indicator 
cell migration. 53 
IX Inactivator activity and chemotactic activity 
generation in miscellaneous sera. 55 
Xll 
LEGENDS TO TABLES 
Page 
Table I. 36 
Table VIII. 54 
Table IX . 56 
Xlll 
LIST OF FIGURES 
Figure Page 
1. Components of the modified Boyden's 
chemotaxis chamber for use with rabbit 
indicator cells . 19 
2. Chemotaxis chamber assembly for use with 
rabbit indicator cells. ...  20 
3. Assembled chamber. 20 
4. View of lower compartment showing injection 
site for the chemoattractant. 21 
5. Close-up view of injection site showing 
passage of needle through the rubber ring 
and into the chemoattractant compartment. . 21 
6. Components of the modified Boyden’s 
chemotaxis chamber for use with human 
indicator cells . 22 
7. Assembled chemotaxis chamber, side view. ... 23 
8. Assembled chemotaxis chamber, top view .... 23 
9. Polymorphonuclear leukocyte indicator cells 
which have migrated completely through 
the micropore filter are visible in the 
first plane of focus. 27 
10. Reduction of serum inactivator activity by 
heating. 40 
11. Comparison of per cent inhibition of 
Group I and Group II sarcoid sera using 
three chemotactic factors as 
chemoattractants. 49 
12. Serum inhibitor in three preparations. 59 
1 
INTRODUCTION 
The clinical manifestations of sarcoidosis were first 
described a century ago by Hutchinson in 1875 (49). Since 
then, numerous investigators have made further contributions 
to the description of the disease but, unfortunately, have 
shed no more light on the cause, prevention or cure of the 
disease. 
Sarcoidosis occurs in many parts of the world with a 
minimum occurrence of 5 per 100,000 in the general popula¬ 
tion (11) and may be hereditary to some degree as familial 
occurrence is more frequent than could be expected from 
statistical data (77). 
The disease has been found in all age groups but occurs 
most frequently between the ages of 20 and 40 years. Both 
sexes appear to be affected with equal frequency (19) and the 
observed over-all mortality is about 6 per cent (79) . 
The modern concept of sarcoidosis is a multi-system 
disorder in which: 1.) well-defined clinicoradiologic patterns 
are associated with 2.) widespread granulomas and 3.) 
depression of delayed-type hypersensitivity (53). These 
three common aspects have been used in the following 
investigative approaches: 
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1.) Diagnostically, the feature most often associated 
with sarcoidosis is the bilateral hilar lymphadenopathy and 
lung involvement with up to 97% of cases showing lung and 
hilar node infiltration (20, 102). This clinicoradiologic 
pattern implicates an unknown airborn antigen which evades 
removal by alveolar macrophages and succeeds in making con¬ 
tact with lymphoid tissue - presumably by way of the 
lymphatics which drain to the hilar nodes. In fact, beryl¬ 
lium, a persistent and indestructible antigen, acts in just 
this way to induce berylliosis, a disease which presents a 
clinical picture similar to sarcoidosis (62). Also, Refvem 
demonstrated that quartz particles and other foreign bodies 
may provoke localized sarcoid formation and suggested that 
calcareous spar found in certain soil types may be the 
initiating agent (73) . Studies of World War II veterans 
with sarcoidosis, geographically represented according to 
the birthplaces of the patients, show the Northeastern and 
Southeastern United States contain the highest concentration 
of cases. These areas are coincident with the pattern of 
sandy soil according to Michael et al (34, 67) and with 
forested or non-arid sections of the country according to 
Cummings et al (19). In conjunction with forested areas, 
3 
plant pathogens or products have been implicated with pine 
pollen being mentioned frequently as a possible suspect (20). 
2. ) Infectious agents can also produce granulomata 
and a picture identical to sarcoidosis leading to incorrect 
diagnoses. Altered or anonymous mycobacteria, acid-fast 
rods, fungus, virus and mycoplasma (14, 16, 52, 54, 74, 75, 
89) among others have all been found in association with 
sarcoidosis, but it remains unclear if the organisms pre- 
ceed the disease or become established due to the patients' 
altered immune response (2, 9). Statistical interpretations 
may prove to be of little value in attempting to pinpoint 
the causative factor because sarcoidosis may be a symptom 
complex rather than an entity. If so, there could be 
numerous etiological agents with no common element to a 
large majority of cases (16). 
3. ) The depressed delayed-type hypersensitivity (DTH) 
reaction characteristically observed in this disease is 
expressed as a cutaneous anergy to a number of common 
antigens. This relative skin unresponsiveness has been 
observed in as many as 75% of sarcoid patients using 
tuberculin as the common antigen (35). Sarcoid patients 
also display decreased responsiveness to Candida albicans, 
4 
histoplasmin, brucelline, coccoidine and mumps antigen 
(32, 48, 51, 71). This feature is of great immunologic 
interest. Normally the DTH response evolves slowly as a 
consequence of a complicated interaction of cell types 
and their products and is mediated by specifically reactive 
thymus-derived lymphocytes (T cells) rather than by con¬ 
ventional antibody molecules. Because this normal sequence 
of events does not occur in a majority of sarcoidosis 
patients and in certain other diseases with widespread 
involvement of the reticuloendothelial system (certain 
neoplasms, Hodgkin's disease, lepromatous type of leprosy, 
disseminated leishmaniasis) (26), these patients may be 
productively studied to determine at what point the reaction 
sequence breaks down and DTH fails to develop in comparison 
to normally responsive control individuals. The investi¬ 
gations can proceed at either cellular or chemical level. 
The study of DTH, itself, is extremely important as this 
reaction seems to be responsible for a number of auto¬ 
immune diseases and allergies and underlies many other 
immune reactions, including resistance to a variety of 
infectious agents, rejection of allografts and resistance 
to most tumors (24). 
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This investigation of the immune surveillance system 
is only one benefit; the other applies directly to the 
welfare of the patient himself. 
The progressive disease course has only one treatment, 
corticosteroid therapy, which is non-specific and not always 
effective (80) resulting in the 670 mortality rate. If, in 
fact, there is no single initiating agent or event responsible 
for the disease, then research dealing with the expression 
and consequences of the syndrome will be most important to 
prevent permanent fibrosis and fatal sequaelae such as bulla 
formation or cor pulmonale. 
This investigation was directed toward the important 
immunological event commonly observed in sarcoid patients - 
the depressed delayed-type hypersensitivity (DTH) reaction 
to a number of common antigens. 
Development of the classic DTH reaction involves 
migration of leukocytes (mostly mononuclear) to the cutaneous 
location of the sensitizing antigen. Both the polymorpho¬ 
nuclear and mononuclear leukocytes have demonstrated directed 
migration along chemical gradients toward a variety of 
complement-dependent and complement-independent chemotactic 
factors. These chemotactic factors can be irreversibly 
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inactivated by a normal serum factor, chemotactic factor 
inactivator (CFI). Inactivation of the chemotactic factors 
by CFI will block the directed leukocyte migration and 
prevent leukocytic accumulation necessary to the expression 
of the classic DTH reaction. Recently, increased levels of 
CFI have been found in the sera of patients with Hodgkin’s 
disease (95). Since both Hodgkin’s disease and sarcoidosis 
display similar cutaneous anergy, it was logical to assume 
high levels of the inactivator in sarcoid sera as well. 
The investigation of the relative amount of CFI (6) in the 
peripheral blood sera from patients with sarcoidosis was 
conducted. This area had not been previously investigated. 
In fact, development of the chemotaxis assay for clinical 
purposes has generated much interest but its use and 
application have been hindered by lack of standardized 
procedures and comparable data. 
The determination of amounts of CFI in sera from 
individuals with sarcoidosis relative to amounts normally 
found in healthy control population could be of diagnostic 
or prognostic value. Further characterization of CFI, 
itself, may lead to a more effective and specific treatment. 
LITERATURE REVIEW 
From an immunological viewpoint, the depressed delayed- 
type hypersensitivity (DTH) reaction expressed as cutaneous 
anergy is the most interesting characteristic of sarcoidosis 
Only a few other conditions present a similar finding and 
these are diseases of a serious or fatal prognosis, such 
as cancers of the reticuloendothelial system, Hodgkin’s 
disease, lepromatous leprosy, final stages of tuberculosis 
and others (29). The fact that sarcoidosis usually presents 
a benign course offers great opportunity to investigate the 
mechanisms of the altered DTH response without the com¬ 
plicating factors incurred in a fatally progressive disease. 
The mechanism of DTH or cell-mediated immunity proceeds 
in this manner: Specific T or thymus-derived lymphocytes 
are activated via antigenic stimulation leading to the 
production of lymphokines. The local release of these 
pharmacologically active substances such as migration 
inhibition factor (MIF), macrophage aggregation factor (MAF) 
a chemotactic factor (CF) , a blastogenic (BF) or mitogenic 
factor (MF) , and a factor which stimulates the metabolic 
activity of macrophages initiate an amplification step 
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mainly involving non-specific recruitment of circulating 
lymphocytes and monocytes. The immigrant monocytes become 
enlarged and altered in appearance due to an increase in 
their content of lysosomes. The protracted time course seen 
in a DTH reaction may be caused by the time needed for 
accumulation of sufficient monocytes and their subsequent 
transfer to activated macrophages (27, 62, 66, 87). 
During peak intensity at 24 to 72 hours, the cellular 
composition of cutaneous DTH reactions shows lesions 
populated exclusively by mononuclear cells which have been 
demonstrated to be lymphocytes and macrophages (23). 
Although 757o of patients with sarcoidosis do not 
respond to tuberculin antigen, passive transfer of tuberculin 
hypersensitivity by means of leukocytes from sensitized 
donors has been achieved, showing that their skin is capable 
of manifesting the DTH reaction (35, 86). 
Both the induction and expression of DTH are a result 
of the activation of specific thymus-derived lymphocytes (22). 
By use of various techniques to differentiate thymus- 
derived (T) lymphocytes from the bone marrow-derived (B) 
lymphocytes (7, 33, 55, 85), patients with sarcoidosis seem 
to have a significantly lower proportion and total number of 
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circulating T cells in their peripheral blood (42). However, 
there have been conflicting reports (63) and the determina¬ 
tion of absolute numbers and of proportions of peripheral 
cells as a measure of immunologic responsiveness is, itself, 
in question (33, 68). 
As very few specific T cells are needed for an in vivo 
allergic response (25), appropriate subpopulations of T 
cells may either be paralyzed by the unknown sarcoid antigen, 
defective, or inactivated by a serum factor. An absolute 
lack of specific T cells does not seem likely as patients 
are able to develop DTH reactions before the onset of the 
disease and begin to return to reactivity after recovery 
(17, 18, 37, 50). 
There are a number of in vitro correlates to DTH by 
which lymphocyte function can be assessed: 
1. Blast transformation of lymphocytes via antigen, 
mitogens or mixed lymphocyte culture 
2. Lymphokine production as determined by: 
A. Effects on macrophages 
B. Cytotoxic effects on cultured cell lines 
C. Recruitment effect on non-sensitized 
lymphocytes (28) 
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Blast transformation of in vitro lymphocyte cultures 
has been assessed by determination of [j^hJ thymidine or l14c: 
leucine uptake, by morphologic lymphoblastic transformation 
and impaired glucose metabolism (8, 56). 
In vitro lymphocyte activation to tuberculin antigen 
correlates with the skin test in sarcoidosis patients and 
parallels results with normal controls. Also, the in vitro 
response to a specific T cell mitogen, phytohemagglutinin 
(PHA), has been largely normal, although these patients dis¬ 
play relative cutaneous anergy (35, 46, 64). Conflicting 
results indicate responses can either be within normal range 
or abnormally depressed (13, 58, 76, 82). Additional studies 
by Mangi, Dwyer, Gee and Kantor have shown a marked disparity 
between cutaneous reactivity to Candida albicans, which was 
abnormal, and the in vitro lymphocyte response to this 
antigen which was normal (64). 
Normal lymphocyte transformation in vitro with 
corresponding in vivo anergy suggests that the lymphocytes 
are not defective but could be coated in vivo by a serum 
inhibitor not found in a well-washed culture. 
Depressed blastogenic responses to Concanavalin A 
(Con A), another T cell mitogen (41), and impaired ability 
11 
to develop cytotoxicity in a mixed lymphocyte culture have 
also been reported (12, 63). 
Unfortunately, accurate interpretations of many reports 
are made difficult due to lack of staging (see Appendix A) 
of the disease and non-comparability of assay systems 
resulting in conflicting reports for virtually every area 
of investigation. 
Correspondingly, some investigators find no correlation 
between cutaneous anergy and in vitro observations or with 
clinical severity of the disease (56). 
Lymphocytes from hyporeactive sarcoidosis patients have 
been shown to produce MIF (3, 61), MAF (38), KMIF (101), 
transfer factor (4, 59, 60), and respond to MF (36). This 
production of lymphokines in vitro enforces the concept 
that the lymphocytes are capable of normal function, but 
they may not be normal in their response to antigen (82). 
The macrophage is the other important cell involved 
in the DTH response. Macrophages from patients with 
sarcoidosis show signs of increased activation as determined 
by an increase in cytoplasmic pyroninophilia (57), and the 
monocytes by increased number of active cells displaying 
higher phagocytic activity and increased IgG receptor 
12 
activity (32) . Macrophages from sarcoidosis patients 
could be substituted interchangeably with normal macro¬ 
phages to enhance tuberculin induced lymphocyte trans¬ 
formation (47), however, normal sensitized control 
macrophages could not reverse the unresponsiveness of 
lymphocytes from patients with sarcoidosis in the presence 
of tuberculin (36). 
Consequently, the mass of evidence indicates that the 
hyporeactivity of the sarcoidosis patient is not due to 
the inability of his skin to express DTH response or of 
lymphocyte and monocyte dysfunction. This heightens the 
possibility of serum factors which could be responsible 
for the altered immunologic state seen in the disease. 
Some investigators have reported various serum inhibitors: 
Plasma from patients with sarcoidosis can significantly 
decrease the response of normal lymphocytes to PHA, even 
when added to optimal concentrations of pooled normal 
plasma (64), suggesting an inhibitor of lymphocyte stimu¬ 
lation. Sera from sarcoidosis patients can also reduce 
the transformation of normal lymphocytes in response to 
Candida and mumps antigens. This factor appears to be 
heat stable at 56°C x 30 minutes (5). 
13 
Caspary and Field (15) have found lymphocytes from 
sarcoidosis patients which are well sensitized to PPD^ 
in vitro while showing negative skin reactions. They 
also believe a serum factor may be responsible for this 
interesting anomaly. 
It has been shown that sensitized lymphocytes, when 
stimulated by the sensitizing antigen, would produce a 
soluble chemotactic factor which would attract large 
numbers of mononuclear cells (97). Such a lymphokine 
would explain the predominance of nonsensitive mononuclear 
cells in the lesions of the delayed skin reaction. The 
chemotactic factor would attract circulating mononuclear 
cells and the migration inhibition factor (MIF) would 
keep them from migrating back out (98). 
A variety of chemotactic factors for neutrophilic 
granulocytes is recognized; many of which are derived from 
the complement system (91). Chemotactic factors include: 
^ Purified protein derivative or PPD is a somewhat 
purified tuberculin product prepared by concentrating the 
active proteins of autoclaved cultures of M. tuberculosis 
by precipitation with ammonium sulfate. 
A standard batch, PPD-S, has been designated as the 
basis for the international unit: 1 tuberculin unit (TU) 
equals 0.02 micrograms of total protein. 
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1. Complement derived factors such as C3 fragment, 
C5 fragment and activated C 567 complex 
2. Soluble bacterial factors 
3. Collagenolytic products 
4. Products of antigen stimulated lymphoid cells 
5. Lysosomal factors in neutrophils (93, 94) 
A variety of chemotactic factors for monocytes is 
also recognized. These factors include: 
1. The trypsin produced C5 fragment, the same one 
which has chemotactic activity for neutrophils, 
and 
2. Lymphokine preparations from antigenically 
stimulated sensitized lymphocytes (95) 
Because of this remarkable diversity of mediators, 
inflammatory response must be kept in balance. Naturally 
occurring inhibitors destroy the kinins and the anaphy- 
latoxins almost immediately upon generation in serum. The 
kinins and anaphylatoxins are inactivated by a serum carboxy- 
% 
peptidase B enzyme, anaphylatoxin inactivator (Al), which 
removes the c terminal arginine residue in the peptides (9). 
A chemotactic factor inactivator (CFI) has also been 
described in normal human serum; the function of which is 
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to provide regulatory control over leukotactic mediators 
generated in serum. This inhibitor isolated from the 
alpha and beta globulin regions of human serum appears to 
act in an enzymatic-like fashion to inactivate complement- 
derived and complement-independent chemotactic factors (6) . 
Imbalances in this naturally occurring CFI appear to 
contribute to various disease courses (43, 92, 99). 
A deficiency of CFI has been shown in patients who 
also have a deficiency of alpha-one anti-trypsin, a major 
trypsin inhibitor. A high percentage of these patients 
develop pulmonary emphysema possibly the result of 
uncontrolled reactions of trypsin-like enzymes. With an 
additional lack of chemotactic factor inactivator to 
inactivate the larger than normal amounts of inflammatory 
mediators which are being generated, a highly disadvan¬ 
tageous situation occurs resulting in inordinate delivery 
of neutrophils and their enzymes to inflammatory 
exudates (100). 
The opposite situation or increased levels of CFI 
have been reported in the serum of patients with Hodgkin's 
disease (95). Patients with Hodgkin's disease fail to 
express DTH reactions to a variety of antigens (1) and 
fail to mobilize inflammatory cells, both neutrophils and 
mononuclear cells in dermal inflammatory sites (72). 
Increased levels of CFI could account for this inadequate 
inflammatory cellular response. 
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MATERIALS AND METHODS 
Human Sera 
Patient Sera: Sera was obtained from two groups of 
patients with radiologically and histologically 
diagnosed sarcoidosis (see Appendix B). 
Group I consisted of eleven patients with sarcoidosis 
diagnosed as Stage II (79). This consists of 
bilateral hilar lymphadenopathy associated with 
pulmonary infiltration, a progressive stage of the 
disease with a 46% chance of resolution. Patients 
were untreated unless otherwise specified. 
Group II consisted of a heterogeneous assortment of 
13 appropriately diagnosed but unstaged sarcoidosis 
patients without regard to therapy. 
Normal Human Sera: Control sera was obtained from 
healthy individuals, many of whom were skin tested 
to common antigens to insure normal cutaneous 
reactivity. 
Miscellaneous Sera: Sera from normal pre-natal 
patients, patients with cirrhotic liver disease, 
cancer and trauma were used in comparison studies. 
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Chemotactic Assays: 
Neutrophil chemotaxis was performed by the micropore 
filter technique using modified Boyden's chemotactic 
chamber (figures 1, 2, 3, 4, 5) and Hill's improved assay 
method (figures 6, 7, 8). These techniques are described 
in detail elsewhere (10, 44, 90). 
Hill's method was also used without employing the 
cytocentrifuge to directly sediment leukocytes on a 
micropore filter. Gravity sedimentation was used for this 
micro method as was used with the modified Boyden's chamber 
and found to be very satisfactory. 
Indicator Cells: 
Rabbit and human polymorphonuclear leukocytes were 
used. 
Assay Procedures: 
Rabbit neutrophils were obtained from a glycogen- 
induced peritoneal exudate collected by a gravity tap In 
heparinized (2-3 drops, 20,000 units per cc, Hiker I.abs, 
Northridge, Ca.) saline, centrifuged at 850-900 R.P.M.'s 
and suspended in Hank's medium (Hank's Balanced Salt: 
Solution, Grand Island Biological Company, Grand Island, 
Figure 1. Components of the modified Boyden's 
chemotaxis chamber for use with rabbit indicator 
cells. 
Screw-in top 
Rubber ring 
Micropore 
filter 
Rubber ring 
Cover glass 
Body of 
chamber 
Injection 
site 
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Figure 2. Chemotaxis chamber assembly for use 
with rabbit indicator cells. 
Figure 3• Assembled chamber; LH - View of 
bottom compartment for chemoattractant, RH - 
View of upper compartment for indicator cells. 
Figure 4. View of lower compartment showing 
injection site for the chemoattractant. 
Figure 5. Close-up view of injection site 
showing passage of needle through the rubber 
ring and into the chemoattractant compartment. 
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Figure 6. Components of the modified Boyden's 
chemotaxis chamber for use with human indicator 
cells. 
Screw-in top which is the 
upper compartment for 
indicator cells 
Micropore filter 
Injection site 
for the chemo¬ 
attractant 
Plug 
This arm-is 
the lower com¬ 
partment which 
holds the chemo¬ 
attractant 
Body of chamber 
Figure 7. Assembled chemotaxis chamber, side 
view. This chamber used for assays using human 
indicator cells. 
Figure 8. Assembled chemotaxis chamber, top 
view. Left hand well receives the chemoattractant; 
right hand well receives the indicator cells. 
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N.Y.) containing 0.05% bovine serum albumin at pH 7.4. 
The upper compartment of each Boyden's chemotaxis chamber 
contained a total of 2.5 x 10^ neutrophils in a total volume 
of one milliliter. The bottom compartment of each chamber 
contained fluids to be tested for chemotactic activity 
(see figures 1, 4, 5), usually 50 microliters chemoattractant 
to 1 milliliter diluting fluid. 
Hank's medium was used for dilution of both cells 
and chemoattractants. Filters of 0.65 micron pore size 
(Millipore Corporation, Bedford, Mass.) were used and 
chemotactic activity quantitated by counting the number 
of cells which had migrated through channels of the filters 
in ten high power fields under light microscopy (10 X 
ocular, 45 X objective). 
Human blood neutrophils were obtained by collecting 25 
milliliters of blood in a sterile disposable plastic 
syringe containing 20 units of heparin (20,000 units per 
cc, Riker Labs, Northridge, Ca.) per milliliter of blood. 
The syringe was placed in a vertical position and the 
erythrocytes were allowed to settle over a 30 to 60 minute 
period. The leukocyte rich plasma was then expressed into 
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sterile, disposable, plastic 12 x 75 millimeter test tubes 
(Falcon Company, Oxnard, California). A suspension of 
polymorphonuclear leukocytes and Tissue Culture Medium 199 
(Microbiological Associates, Inc., Bethesda, Maryland) was 
prepared with a count of approximately 0.6 x 10^ cells per 
milliliter; 0.1 milliliter of this suspension was diluted 
to 0.4 milliliter with Medium 199 and deposited in the 
top compartment of the chemotactic chamber. The bottom 
compartment holds the attractant also diluted in Medium 199 
(see figure 6). Filters of 5 micron pore size (Millipore 
Corp., Bedford, Mass.) were used and chemotactic activity 
quantitated by counting the number of cells that have 
migrated completely through the filter within ten random 
fields at high power (10 X ocular, 45 X objective) using 
light microscopy. 
After incubation of either type of chemotaxis chamber 
for three hours at 37°C, the filters were removed and 
dipped as rapidly as possible in absolute isopropyl alcohol 
for fixation. The filters were then taken through a 
staining procedure: 
1. Hematoxylin (Harleco, Philadelphia, Pa.) - 
2 minutes 
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2. Water rinse 
3. Acid alcohol (3-4 drops HCL in 70% isopropyl 
alcohol) - 30 seconds 
4. Water rinse 
5. Bluing agent (20 grams Mg SO^ - 7^0, and 2 
grams NaHCO^ in one liter distilled t^O) - 
2 minutes 
6. Water rinse 
7. 70% isopropyl alcohol - 30 seconds 
8. 95% isopropyl alcohol - 30 seconds 
9. 100% isopropyl alcohol - 30 seconds 
10. 100% isopropyl alcohol - 1 minute 
11. 100% xylene - 5 minutes 
12. 100% xylene - 5 minutes 
Then the filters were mounted on slides with Permount 
(Fisher Scientific Co., Fairtown, New Jersey) lymphocyte 
side down and polymorphonuclear leukocyte side up and 
covered with a glass cover slip. The attractant surface 
of the filters was mounted upward so that the cells which 
had migrated completely through the filter were visible in 
the first plane of focus (see figure 9). 
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Figure 9. Polymorphonuclear leukocyte 
indicator cells which have migrated com¬ 
pletely through the micropore filter are 
visible in the first plane of focus. 
Hiffh power (X12 X45), light microscopy. 
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Viability of cells as revealed by Trypan blue 
exclusion (40) was 98% in all preparations. The Trypan 
blue test: 1 drop Trypan blue (Direct Blue Biological 
Stain, Matheson, Coleman & Bell Manufacturing Chemists, 
Norwood, Ohio) at 1 milligram/milliliter saline combined 
with 1 drop of a cell preparation plus 1 drop of homo¬ 
logous serum. After incubation for 15 minutes at 37°C, 
cells were examined under light microscopy for evidence 
of bluing which indicates cell death with concomitant 
increase in permeability. 
A nitro-Blue Tetrazolium (NBT) ( [j., 21 Di-P- 
Nitrophenyl-5, 51 - diphenyl-3, 31- (3, 31-dimethoxy-4, 
diphenylene) ditetrazolium 
Grade III, Sigma Chemical Corp., St. Louis, Missouri) 
assay was conducted on all normal and abnormal human cells 
as an indicator of phagocytic activity (45, 81). No 
abnormal findings occurred in any cell preparation 
indicating all subjects had polymorphonuclear leukocytes 
qualitatively capable of normal phagocytosis and will not 
be referred to again in this paper. For each test 5 x 10 
to 1 x 107 cells in Medium 199 was combined with 0.1 
milliliter homologous serum, 2 milligram Zymosan A 
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(Sigma Chemical Company, St. Louis, Missouri) and 0.1 
milliliter NBT (2 milligram/milliliter). Phagocytosis 
was assayed as the reduction of the NBT dye which was 
visualized as a definite blue color after incubation for 
1 hour at 37°C. 
Chemotactic Factors: 
Preparation of chemotactic bacterial factor: Bacterial 
factor was obtained from 24 hour culture supernatants (in 
Hank's medium) of Escherchia coli sterilized by filtration 
through a 0.22 micropore filter and frozen in 3 milliliter 
aliquots at -70°C. Fifty microliter/milliliter of this 
factor was used unless otherwise indicated. 
Preparation of complement chemotactic factors: Human 
C3 and C5, purified according to the method of Nilsson and 
Muller-Eberhard (69), were kindly supplied by Dr. P. A. 
Ward, Farmington Health Center, Connecticut. Chemotactic 
fragments of C3 were produced by treatment with trypsin 
(Mann Research Labs, Inc., New York) according to the 
\ 
procedure of Bokisch & Muller-Eberhard (9). 
In a similar manner chemotactic fragments of C5 were 
prepared by trypsinization (96). Purity and specificity of 
the preparations were tested by Ouchterlony double 
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diffusion - double dimension agar precipitation test (see 
Appendix C) using appropriate antisera which was also 
supplied by Dr. Ward. 
C3a an<^ ^5a activity was produced directly in normal 
human serum by the method of Vallota and Muller-Eberhard 
(88): Epsilon-aminocaproic acid (EACA) (IM) (epsilon- 
Amino-n-Caproic Acid, Sigma Chemical Co., St. Louis, Mo.) 
was combined with normal human serum and incubated for 90 
minutes yielding EACA (0.5M) is combined with normal 
human serum and treated with 20 milligram/milliliter of 
boiled (30 minutes) baker's yeast at 37°C for 75 minutes 
yielding C$a. 
Zymosan Activation of Serum Complement: 
The alternate pathway for complement activation was 
triggered in both normal and patient sera using Zymosan 
as the initiating agent (21). To compare relative complement 
levels in patients and controls, Zymosan A (0.5 milligrams 
per 50 milliliters serum) was incubated 30 minutes at 37°C 
to activate the third through ninth components of complement 
with the production of chemotactic activity. 
Assay for Chemotactic Factor Inactivator (CFI): 
CFI levels were determined by combining 50 microliters 
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test serum with 50 microliters of a chemotactic preparation 
and incubating this mixture at 37°C for 30 minutes and then 
60 minutes at 56°C. Each sample was then diluted to 1 
milliliter with either Hank's (for rabbit cells) or Medium 
199 (for human cells), depending upon the indicator cells 
used in the assay system. This was injected into the lower 
compartment, or attractant side of the chamber (see figures 
1, 6). Irreversible inactivation of the chemotactic factor 
by CFI was indicated by decreased migration of indicator 
cells through the micropore filter in this test chamber as 
compared to the migration seen in control chambers. Control 
chambers were loaded with 50 microliters of chemotactic 
factor incubated with 50 microliters normal human serum at 
37°C for 30 minutes and then inactivated at 56°C for 60 
minutes. 
Assay for Cell-Directed Mediators: 
Bacterial factor (50 microliters) diluted to 1 
milliliter with Medium 199 was placed in the lower chamber. 
The upper chamber contained human polymorphs which had 
been previously incubated with either 10% patient or 10% 
normal control serum for 30 minutes at 37°C and then washed 
with Medium 199. 
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Assay for Relative Serum Complement Levels: 
Rabbit neutrophils were used as the indicator cells 
with Zymosan activated sera (50 microliters) as the 
attractant. 
Ultracentrifugal Studies: 
Ultracentrifugal characteristics of patient whole, 
unconcentrated serum and a normal serum extract (obtained 
with ammonium sulfate at 40% saturation, the soluble 
fraction dialized against phosphate buffered (pH 7.3) 
saline (PBS)^ and then concentrated to 1/3 the original 
volume of serum) were determined by fractionation in a 
sucrose density gradient (7.5 - 35% sucrose in phosphate 
buffer, pH 7.3, ionic strength 0.05) with centrifugation 
at 55,000 R.P.M.'s for 16 hours at 40°C in an International 
Hematocrit Centrifuge (International Equipment Company, 
Boston, Mass.) B-60 using a swinging bucket rotor. 
Calculations: 
In most cases, results were recorded as per cent 
inhibition which was determined by calculating the ratio 
Phosphate buffer saline is prepared by combining 
160 grams NaCL, 27.6 grams NaH2 PO4-H2O, 16 milliliters 
40% NaOH (6.4 grams) and distilled H2O up to a volume of 
20 liters; pH to 7.4. 
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of chemotactic activity in the presence of the inactivator 
and in its absence, times 100 and then subtracting from 
100; or using this formula: 
A ~ B x 100 = Per cent inhibition 
A 
where A is the sum of cells in 10 fields using normal 
human serum as the source of CFI 
where B is the sum of cells in 10 fields using patient 
serum as the source of CFI 
34 
RESULTS 
Chemotactic Factor Inactivator in Normal Human Sera 
Fourteen samples of fresh and frozen (-70°C) normal 
human sera (NHS) were tested for CFI activity using 
rabbit polymorphonuclear leukocytes in 0.057o bovine 
serum albumin (BSA) as the indicator cells. Prepared 
bacterial factor (bf), C3 fragments and C5 fragments 
were used as the attractants in modified Boyden's 
chemotaxis chambers. 
The data in Table I are representative of the general 
findings concerning test values and ranges of CFI and 
chemotactic responses in normal human sera. 
Table I indicates degree of inactivation of chemo¬ 
tactic factors after incubation with NHS samples. The 
numbers represent the actual counts of indicator cells 
which have migrated through the micropore filters in 
response to chemotactic factors alone or after incubation 
with the NHS samples. Sample #6 is the serum from which 
the C3 and fragments were obtained. The lack of 
migrational response of indicator cells indicates that 
this serum was not originally chemotactic. Similarly, 
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Legend to Table I 
* The numbers are direct counts of indicator cells 
which have migrated through the filter in ten random 
fields under high power, light microscopy. 
** Sample #6 is the serum from which and 
fragments were obtained. 
*** Indicates serum inactivated by heating at 
56°C for 60 minutes prior to incubation with the 
chemotactic factors. 
The test counts represent cell migration to 50 
microliters of the complement-dependent chemotactic 
factors and to 100 microliters bf incubated with 
50 microliters NHS for 30 minutes at 37°C, followed 
by assay set up. Difference between test counts 
and control counts minus background migration can 
be used to calculate percent inhibition. Direct 
counts from assays in which the chemotactic factors 
were incubated with serum show decreased migration. 
Normal human sera incubated with chemotactic factors 
resulted in an average 20% migration inhibition of 
indicator cells. 
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use of serum alone as the chemoattractant indicates that 
the sera samples are not in themselves chemotactic. 
As indicated in Table I normal serum incubated with 
chemotactic factor (bacterial factor or fragments) 
resulted in an average 20% migration inhibition of 
indicator cells compared to controls of chemotactic 
factors incubated without serum. Chemotactic C3 fragments 
responded erratically often showing increased migration of 
indicator cells when incubated with normal human serum 
(NHS). 
Values for test sera are calculated against normal 
serum controls in order to correct for the slight inhibition 
of normal sera. The serum and negative control values are 
considered to be background migration and are routinely 
subtracted from test counts prior to calculation of per 
cent inhibition. 
The fresh sera tested were found to react as the 
frozen specimens. A number of combinations pooled among 
the frozen samples and a number of pools of fresh serum 
reacted erratically and could not be used to prepare a 
single lot of control serum. The reason for the erratic 
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behavior of pooled specimens can only be conjectured, 
perhaps being related to some unknown serum factors or 
factor incompatibility. Sera could be frozen, thawed and 
refrozen a minimum of three times without loss of repro¬ 
ducibility. All sera collected for this investigation 
were treated in like manner - fresh blood sera were 
tested immediately, the remainder being aliquoted into 
small vials and frozen at -70°C with no serum aliquots 
o 
refrozen more than three times. The assay was found to 
yield cleaner results when the sera, either normal or 
patient, were heat inactivated by heating at 56°C for 
60 minutes following the 30 minute incubation with a 
chemotactic factor at 37°C. 
Heat inactivation prior to testing effectively reduced 
CFI activity even in the low levels contained in normal 
human sera. This is shown in Table II and Figure 10. 
Bacterial factor was found to remain chemotactic 
for polymorphonuclear leukocytes at temperatures up to 
60°C. However, at temperatures higher than 56°C, test 
serum proteins coagulate yielding unacceptable results. 
All tests using bacterial factor as the attractant and 
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REDUCTION OF SERUM INACTIVATOR ACTIVITY BY HEATING 
Figure IQ. Heat inactivation of serum = 56°C X 60 min.) 
prior to incubation with bacterial factor produced marked 
reduction in serum inactivator activity indicating that CFI 
is heat labile. 
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all the serum controls were subjected to heat inactivation 
prior to chemotaxis assay. 
Using information such as found in Tables I and II, 
a number of normal serum samples were selected according 
to their similarity of response with bacterial factor in 
the assay system. These aliquots were utilized as control 
sera in those tests not requiring autologous serum. A 
minimum of three different normal control sera was 
included in each assay to insure a normal range value 
with which to compare test sera values. 
Chemotactic Factor Inactivator in Sera of Patients with 
Sarcoidosis 
The data in Tables III and IV indicate that 
unfractionated, non-concentrated sera from patients with 
sarcoidosis show significant inhibition of the chemotactic 
activity. In some sera, greater than 80% of chemotactic 
activity was destroyed although such high results were 
not obtained within the Stage II group of patients' sera. 
The Zymosan activation of sarcoid sera showed normal 
generation of the complement-dependent chemotactic factors 
(complement components three through nine) via the 
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Table III. 
Bacterial factor inactivator in Group I sarcoid sera 
Serum tested 
(coded) 
Inactivation of bf* 
(per cent inhibition) 
Chemotactic activity 
generated in serum** 
(per cent) 
B.T. 0 100 
I.B. 47 97 
E.B. 51 90 
A • B • 63 95 
G.C. 51 93 
D.S. 54 66 
J.D. 27 80 
L.S. 69 100 
C.D. 48 - 
F.K. 0 93 
R. C. 65 
* Assays were conducted by incubating 50 microliters 
serum with 100 microliters bacterial factor. Per cent 
inhibition of normal control serum is taken to be 
** Generation of chemotactic activity via the alternate 
pathway was accomplished in the sarcoid sera by incubating 
three milligrams zymosan to 0.1 milliliter serum at 37°C for 
30 minutes and testing the serum so treated for chemotactic 
activity. Per cent activity in normal control sera is taken 
to be 100^. 
Group I (Stage II) sarcoid sera have elevated levels of 
chemotactic factor inactivator. These sera are generally 
normal in their ability to generate chemotactic activity 
following treatment with zymosan. This generated activity 
appears to be resistant to the effects of increased levels of 
serum inactivators. 
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Table IV. 
Bacterial factor inactivator in Group II sarcoid sera 
Serum tested 
(coded) 
Inactivation of bf* 
(per cent inhibition) 
Chemotactic activity 
generated in serum** 
(per cent) 
#i 71 85 
2 88 90 
3 71 100 
4 59 99 
5 75 100 
6 61 100 
7 53 - 
8 78 100 
9 56 90 
10 85 - 
11 66 90 
12 85 90 
13 67 100 
* Assays were conducted by incubating 50 microliters 
serum with 100 microliters bacterial factor. Per cent 
inhibition of normal control serum is taken to be 0^. 
** Generation of chemotactic activity via the alternate 
pathway was accomplished in the sarcoid sera by incubating 
three milligrams zymosan to 0.1 milliliters serum at 37°C for 
30 minutes and testing the serum so treated for chemotactic 
activity. Per cent activity in normal control sera is taken 
to be 100^. 
Group II (unstaged) sarcoid sera possess elevated levels 
of chemotactic factor inactivator. These sera show normal 
chemotactic activity generation which seems resistant to the 
effects of the increased levels of serum inactivators. 
alternate pathway in these sera. Response of normal serum 
controls was assigned a value of 100% to which the sarcoid 
sera were compared. 
Chemotactic Factor Inactivator in Group I Sera 
As determined by irreversible bacterial factor 
inactivator, eight of eleven patients showed greater than 
47% inhibition with a mean of 43%, and standard deviation of 
t 12. These results in Table III were obtained using 50 
microliters of sera incubated with 50 microliters bacterial 
factor at 37°C and inactivated for 60 minutes at 56°C. 
This preparation was used as the attractant after dilution 
to one milliliter^with either Hank's or Medium 199, 
depending on indicator cells used. Both rabbit and human 
cell systems gave comparable results. 
Chemotactic Factor Inactivator in Group II Sera 
As shown in Table IV, all thirteen sera in this 
heterogenous group showed greater than 50% inhibition with 
the mean of 70% inhibition of chemotactic activity as com¬ 
pared to normal controls and standard deviation of ^ 10. 
Specificity of the Chemotactic Factor Inactivator 
The data presented in Table V and Table VI indicate 
selective inactivation of the complement derived frag¬ 
ment in preference to the fragment. Where performed, 
this selective inactivation is significant in the Stage II 
patients of Group I. 
In Group II the results are variable with only five 
of thirteen showing this selective inactivation. Three 
of thirteen had no inhibition with either or frag¬ 
ment preparation, two showed equal amounts of inactivation 
and only one selectively inactivated the C5 fragment 
preparation. Although this group showed variability in 
specificity, it uniformly exhibited inhibition when 
bacterial factor was used as the attractant. These finding 
suggest that selection of patients with regard to staging 
of the disease course would be of great importance if 
comparable serological results are to be obtained. Con¬ 
versely, the percent inhibition of the C3 fragment deter¬ 
minations may be an important indicator as to the 
progression of the disease into Stage II. 
In both groups of sera, the percent inhibition as 
measured by inactivation of bacterial factor did not 
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Table V. 
Specificity of chemotactic factor inactivator in 
Group I sarcoid sera 
Serum tested 
(coded) 
Inactivation of chemotactic factor* 
(per cent inhibition) 
C3 fragment C5 fragment Bacterial factor 
B.T. 52 02 0 
I.B. 03 02 47 
E.B. 42 10 51 
A.B. 28 12 63 
G.C. 38 09 51 
D.S. 10 02 54 
J.D • 36 01 27 
L.S. 46 03 69 
C.D. 14 0 48 
* Values represent per cent inhibition calculated on the 
basis of activity of chemotactic factor incubated with patient 
serum as compared to activity of the factor incubated with 
normal control serum. Per cent inhibition of normal control 
serum is taken as 0fo. 
Chemotactic factor inactivator in Group I (Stage II, 
untreated) sarcoid sera shows selective inactivation of the 
chemotactically active C3 fragment. 
The chemotactic fragments of the third and fifth components 
of human serum complement were produced by treatment of 56 micro¬ 
grams purified C3 and C5 with 5 micrograms trypsin in 50 micro¬ 
liters phosphate buffered saline, with incubation at 37°C for 
five minutes. Reactions were terminated by addition of 10 micro¬ 
grams soybean trypsin-inhibitor. Fragments of C3 and C5 were 
also produced by treatment with EACA as described elsewhere. 
Fifty microliters of the C3 and C5 fragments were incubated 
with 10 microliters serum. One hundred microliters bacterial 
factor was incubated with 50 microliters of serum. 
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Table VI. 
Specificity of chemotactic factor inactivator in 
Group II sarcoid sera 
Serum tested 
(coded) 
Inactivation of chemotactic factor* 
(per cent inhibition) 
C3 fragment C5 fragment Bacterial factor 
#1 46 73 71 
2 65 03 87 
3 25 26 71 
4 30 14 59 
5 14 0 75 
6 49 0 6l 
7 - - 53 
8 0 0 78 
9 0 0 56 
10 59 0 85 
11 02 08 66 
12 24 20 85 
* Values represent per cent inhibition calculated on the 
basis of activity of chemotactic factor incubated with patient 
serum as compared to activity of the factor incubated with 
normal control serum. Per cent inhibition of normal control 
serum is taken as 0^. 
Chemotactic factor inactivator in Group II (unstaged, 
treatment unknown) sarcoid sera shows selective inhibition of 
the chemotactically active C3 fragment in only 5 of 11 samples. 
Production of the chemotactic factors and quantities used 
are as outlined in Table V. 
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correspond with the degree of inhibition of the other 
chemotactic factors. For example, in Group I, E.B. had 
51% inhibition of bacterial factor and 42%, inhibition 
of the fragment preparation while D.S. with 54% 
bacterial factor inhibition only showed 10%, fragment 
inactivation. These data are graphically represented 
in Figure 11. 
Zymosan Studies 
In an attempt to demonstrate the ability of patho¬ 
logical sera containing high levels of CFI to be normal 
in its generation of complement-dependent chemotactic 
activity, Zymosan was used to activate the complement 
sequence in sera via the alternate pathway. Tables III 
and IV show that this Zymosan generated complement- 
dependent chemotactic activity is normal. These data 
do not preclude the possibility that there may be an 
earlier deficiency (before C3) in the complement sequence. 
Heat Inactivation Studies 
In order to determine the stability of the chemotactic 
factor inactivator, the sarcoid sera were incubated at 
56°C for 60 minutes prior to the addition of the bacterial 
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factor. The remaining steps of the assay were followed 
as before except for the final 60 minutes of heat 
inactivation at 56°C which was eliminated as it did not 
alter the results. 
The data in Table VII show that there is an average 
of 22% increase activation in Group I sera (Sarcoidosis 
Stage II) with prior heat inactivation. Percent increase 
activation was calculated by comparing indicator cell 
migration from those tests using sera not heat inactivated 
and those using the same sera subjected to heat inactivation 
prior to'incubation with a chemotactic factor. Group II 
show more variability with an average of 122% increase 
activation using twelve out of thirteen sera. 
Cell-Directed Mediator 
In order to determine if the serum inactivator works 
directly on the indicator cells rather than on the chemo¬ 
tactic factor, indicator cells of patients or normal 
controls were incubated for 30 minutes at 37°C with 107. 
homologous or 10% autologous serum. These cells were 
washed in Medium 199 and used in the assay system with 
bacterial factor or Zymosan activated normal human serum 
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Table VII. 
Heat lability of serum chemotactic factor inactivator 
Serum tested 
(coded) 
Per cent increased migration 
(enhancement) of indicator cells* 
Group I B.T. 0 
E.B. 15 
I .B. 37 
A.B. 28 
G.C. 36 
D.S. 19 
R.C. 0 
J.D. 13 
L.S. 42 
Group II #1 344 
2 167 
3 281 
4 244 
5 100 
6 83 
7 33 
8 58 
9 31 
10 78 
11 158 
12 50 
13 07 
Controls 
NHS #1 0 
NHS #2 0 
NHS #3 0 
NHS #4 0 
Pool 1-4 #5 0 
* Indicator cell migration toward 50 microliters serum 
incubated with 100 microliters bacterial factor wasQcompared 
to migration toward 50 microliters heated serum (56°C for 60 
minutes) which was then incubated with 100 microliters 
bacterial factor. Per cent enhancement was calculated as 
this ratio minus 1.00. For clarity, NHS controls were taken 
as zero per cent enhancement. The actual 17$ enhancement 
(average value in a range from 0 to 32$) obtained from heat 
inactivation of NHS has been subtracted from the values 
given for sarcoid sera. 
Substantial per cent enhancement of migration toward 
bacterial factor incubated with the heated sera indicates 
that serum chemotactic inactivator is heat labile at 56°C. 
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as the attractant. 
Eight patients were tested and a wide variety of 
results occurred. Three of eight subjects had cells which 
showed 36%, 50% and 60%, inhibition when incubated with 
autologous serum as compared to cells incubated with 
homologous normal human serum. Three of eight showed 
no difference if patients' cells were incubated with 
either autologous patient serum or normal serum. Two of 
eight were enhanced in their migration through the filter 
toward the chemotactic factor by their own serum and 
actually inhibited by the normal serum. One patient 
showed enhancement by his own serum to bacterial factor 
and similar percentage inhibition when Zymosan-activated 
NHS was used as the chemoattractant. These data are 
represented in Table VIII. 
Miscellaneous Studies 
Table IX represents various data from non-patho- 
logical and pathological sera. 
Cirrhotic Liver Diseases 
Four patients with cirrhotic liver disease were found 
to have between 37% and 57% inhibition. These results have 
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Table VIII. 
Effects of sarcoid sera on indicator cell migration 
Sarcoid indicator 
cells in 10% 
autologous serum 
(coded) 
Chemotactic 
factor 
Per cent 
Inhibition 
Per cent 
Enhancement 
Cells B.T. bf 50 0 
NHS-Z* 50 0 
I .B. bf 36 0 
NHS-Z 32 0 
E.B. bf 0 42 
NHS-Z 50 0 
G.C . bf 0 0 
A.B. bf 0 0 
NHS-Z 0 0 
D.S. bf 0 0 
NHS-Z 0 0 
J.D. bf 0 0 
F.K. bf 0 27 
Normal human 
indicator cells Chemotactic Per cent Per cent 
in 10^ sarcoid factor Inhibition Enhancement 
serum (coded) 
Serum G.C. bf 0 43 
A.B. bf 0 0 
D.S. bf 0 0 
NHS-Z 0 0 
F.K. bf 0 27 
* NHS-Z was prepared by adding 0.5 milligrams zymosan 
to 50 microliters normal human serum and incubated at 37°C 
for 30 minutes. 
Legend to Table VIII 
Indicator cells, whether sarcoid or normal, were 
incubated with fresh autologous or fresh homologous 
serum (107.) for 30 minutes at 37°C. 
Where sarcoid cells were used, the difference 
between migration toward the chemoattractant of 
cells incubated with autologous serum and cells 
incubated with normal human serum were calculated. 
Both per cent inhibition and per cent enhancement 
were calculated by comparing the counts of cells 
in 107, sarcoid serum to these cells in 10% normal 
human serum. Four out of eight patients appeared 
to have no correctible serum defect which acted 
directly on the cells. 
Sarcoid serum produced no inhibition when incubated 
with normal human indicator cells. Two of four 
produced migration enhancement. 
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Legend to Table IX 
* Total white blood count and differential count 
were performed by the hospital hemotology laboratory. 
** Serum sample #7 was obtained from a patient in the 
terminal stage of his disease. 
Assays to determine inactivation of bacterial factor 
by miscellaneous sera were conducted using 10 micro¬ 
liters serum to 200 microliters bacterial factor. Per 
cent inhibition was calculated using normal human serum 
incubated with bacterial factor as a comparison value, 
taken to be 0%>. 
Chemotactic activity generation was determined using 
0.5 milligram zymosan in 50 microliters serum and 
incubated at 37°C for 30 minutes. Per cent activity 
in normal control sera is taken as 100%. 
The determination of per cent increased migration was 
performed by heating test sera for 60 minutes at 56°C 
prior to incubation with bacterial factor. 
' The per cent increase in migration is calculated as 
the ratio of the test chemotactic value (number of 
cells migrating in ten random fields, high power light 
microscopy) to the control value using normal human 
serum, minus 1. 
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been corroborated by Dr. E. G. Maderazo of the Research 
Department of the Hartford Hospital, Hartford, Connecticut 
(personal communication). 
Hodgkin's Disease 
Three serum samples (supplied by Dr. Peter A. Ward, 
University of Connecticut Health Center) revealed 
elevated levels of CFI and specificity for the C5 fragment. 
Cancer 
Sera from seven patients with cancer were tested for 
CFI with special attention to cases in which the neoplasia 
occurred in the lung. All of these patients were receiving 
therapy. Results were variable as expected. Two of seven 
appeared to have normal CFI levels. The others showed 
between 68%, and 20% inhibition. The ability of these 
sera to generate complement-dependent activity is mixed. 
Prenatal Normal 
Two pools of twenty-four sera from healthy pre-natal 
patients were tested, yielding normal levels of CFI. 
High White Count 
Five sera from hospital patients with high white 
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o 
counts, 14,200 - 21,400 cells per mmJ with greater than 
88% polymorphonuclear leukocytes, were tested for CFI. 
These patients were traumatized accident victims with no 
known underlying pathological condition. With one exception, 
no abnormal levels of CFI were found in this group. One 
patient with a 30,000 white count did show significant 
migration inhibition but no follow-up studies were possible 
to rule out an unknown underlying disease condition. 
Physical-Chemical Features of CFI in Sarcoidosis Sera 
It has been shown that CFI in normal human serum can 
be fractionated into two distinct components, each with 
CFI activity, for bacterial chemotactic factor (39). 
Normal and sarcoidosis sera were separated by sucrose 
density gradient. The fractions were incubated with 50 
microliters bacterial factor at 37°C for 30 minutes, and 
this mixture assayed for residual chemotactic activity. 
Figure 12 shows the comparison of normal serum to 
two test sera from patients who showed high levels of CFI. 
One patient serum was selected from Group I and the other 
from Group II. 
In each of the three preparations, a strikingly 
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SERUM INHIBITOR IN THREE PREPARATIONS 
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Figure 12. Analysis by sucrose density gradient ultracentri¬ 
fugation of CFI in fractions of sarcoid sera and from an 
extract of normal serum (obtained with ammonium sulfate at 40fo 
saturation)* Biphasic activity of CFI is similar in all 
three preparations. 
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similar pattern was observed: biphasic inactivator activity 
appeared in the IgG marker position, with the second 
position between albumin (BSA) and cytochrome markers. 
These data indicate that CFI in sera from sarcoidosis 
patients cannot be distinguished from CFI present in normal 
human serum on the basis of ultra-centrifugal features. 
Preliminary studies seem to point to selective inactivation 
of complement-derived fragments by each peak. One peak may 
inactivate the C3 fragment and the other the C5 fragment. 
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Discussion 
Although a practical method was developed by Boyden 
in 1962 (10) to assay leukotaxis, this valuable tool has 
not been utilized effectively in clinical situations. 
The reasons are twofold: 
1. Studies of leukotaxis in research were done on 
individual bases providing little standardization of 
procedures with resultant difficulty in comparison of 
data. 
2. Little progress has been made in the investigation 
of the leukotactic responses which occur in various disease 
states as compared to that found in a normal population. 
Consequently this investigation had a dual approach. 
First, it outlined a simple, reproducible procedure 
adaptable to a clinical laboratory situation. No elaborate 
apparatus was required and the 25 milliliters of whole 
blood needed for testing leukocyte mobility and CFI activity 
is a reasonable quantity easily obtainable on a routine in¬ 
patient basis. Second, leukotactic function was assayed 
in a variety of pathological as well as normal conditions. 
Rabbit leukocytes were demonstrated to function inter- 
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changeably with human leukocytes in their ability to 
respond to measured levels of chemoattractants. This sub¬ 
stitution of animal for human leukocytes as indicator cells 
would be invaluable in the event that the required quantity 
of whole blood could not be obtained. 
The disease of major concern was sarcoidosis. It was 
found that the sera of these patients contained an 
inactivator of a variety of experimentally produced chemo¬ 
attractants. The chemotactic factor inactivator (CFI) was 
easily visualized in a leukotactic assay. 
Two groups of patients with sarcoidosis were selected 
for this study in an attempt to determine if staging of 
the disease would be significantly reflected in the results. 
Group I was composed of sera from Stage II individuals 
representing an active state of the disease which had not 
yet been treated, especially with steroids, the only method 
of therapy. Group II was composed of sera from randomly 
chosen sarcoid patients, both unstaged and with unknown 
status of current therapy. 
The reasons for the choice of Group I include: 
1. Possible influence by corticosteroids would be 
eliminated and 
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2. Restriction to a designated stage of a sometimes 
protracted illness would be useful for comparing test 
results and could be indicative or predicative of disease 
course. 
Accordingly, corticosteroids have been shown in 
vitro to inhibit lymphocyte transformation (39) , inhibit 
mitosis (70) , and reduce response to PHA (63) but do not 
affect the ability of monocytes and polymorphonuclear 
leukocytes to either phagocytize or kill (30, 31). In 
vivo, steroids have been shown to produce a paradoxical 
skin reaction in approximately one-third of all sarcoidosis 
patients (40, 87). The inability of the skin of these 
patients to respond to PPD and lymphokine (from 
Concanavalin A stimulated lymphocytes) can be reversed 
by an injection of corticosteroid. Prednisone can cause 
a previously non-responsive site to respond to a prior 
PPD injection (40). This is exactly opposite to the 
effect in normal persons and indicates that patients 
with sarcoidosis have a block distal to lymphocyte 
function correctable by steroids. This paradoxical 
response does not occur in other anergic states such as 
cancer. 
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Staging of the disease is also desirable as investi¬ 
gators who have compared the stages indicate Stage II 
correlates with the anergic state in vivo, reduced PHA 
transformation, depressed cytotoxic capacity and significant 
migration inhibition in vitro (3, 12, 47). 
Results of the grouping were not striking when 
bacterial factor was used as the chemoattractant in the 
chemotaxis assays (Figure 11). However, the selective 
inactivation of the C3 fragments was apparent in Group I, 
indicating a real need to classify results of investiga¬ 
tions according to the stage of the disease in order to 
get comparable data. It seems especially important in a 
disease such as sarcoidosis which can become chronic and 
persist for years or which can spontaneously resolve 
itself at any point along an active and sometimes fatally 
(6%) progressive disease course. 
Throughout the study, it became apparent that the 
chemotaxis assay is very sensitive and responds to minute 
amounts of reactants. Bacterial factor can be made up in 
large quantities and frozen in aliquots for long term 
usage. It is very stable at both low (-70°C) and high 
(60°C) temperatures and is homogeneous from aliquot to 
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aliquot yielding highly reproducible results. 
The complement derived fragments are prepared from 
human sera and as such may bring interfering or enhancing 
factors into the reaction. 
It is interesting to note, coincidentally, that persons 
reaching Stage II have a 45% chance of resolution of the 
disease, these data show an average 47% inhibition in this 
group, and Becker et al reported 43% of sarcoid patients 
(Stage II) exhibit migration inhibition using the leukocyte 
migration assay (13). 
As shown by the data, there appears to be a defect in 
the ability of sera from sarcoidosis patients to regulate 
chemotactic mediators. 
In each defective serum an excessive inactivation 
of chemotactic activity is found. The supernormal levels 
of chemotactic factor inactivator (CFI) possess the ability 
to inactivate leukotactic mediators that are both complement- 
derived and complement-independent (Figure 11). CFI also 
inactivates lymphocyte-derived chemotactic factors and 
can inactivate chemotactic factors for monocytes, as well 
as for neutrophils (91, 97). This generalized action 
along with elevated levels of CFI found in sarcoid sera 
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are consistent with the clinical observation of impaired 
delayed-type hypersensitivity (DTH) responses in the 
sarcoid patients. 
Investigations of the histology of DTH reactions in 
the skin have shown early (2-3 hours) migration of 
polymorphonuclear leukocytes especially around areas of 
cellular damage along with mononuclear infiltration. 
Mononuclear cells quickly dominate the picture, possibly 
due to the more rapid disintegration of the polymorphs 
resulting in 86% lymphocytes and 14% macrophages in the 
perivascular cell infiltrate at peak reaction (48 - 96 
hours) (84). 
A majority of cells which make up.the infiltrate 
are not specifically sensitized cells (66) and are derived 
from the blood (36). The mechanism for the accumulation 
of these cells involves mediation by various chemotactic 
factors (83, 90, 91, 93, 94, 99). Inactivation of these 
factors by CFI must play a significant role in a variety 
of pathological and non-pathological conditions. Abnormal 
levels (low as in alpha-one anti-Trypsin deficiency and 
elevated as in Hodgkin's disease) have already been shown 
to coincide neatly with clinical findings and disease 
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manifestations (95, 100). As in Hodgkin's disease, sera 
from sarcoid patients show elevated levels of CFI expressed 
by increased inactivation of chemotactic factors. These 
two diseases are also similar in that they both express 
cutaneous anergy. 
Physical-chemical studies of sarcoid sera indicate a 
bimodal activity of serum CFI. In ultracentrifugal 
preparations this biphasic activity is comparable to that 
of CFI found in normal human serum (Figure 12) and cannot 
be distinguished from it. This finding and others of 
Dr. Peter A. Ward (6) indicate that the heterogeneity of 
this inactivator is due to two separate and distinct 
substances. 
This concept is reinforced by the data in Tables III 
and IV and Figure 11 showing that the CFI in sera from 
sarcoid patients of Group I (Stage II) selectively 
inactivates the C3 chemotactic fragment. Since CFI in 
sera from Hodgkin's patients fails to inactivate the C3 
fragment (95) (contrasted with CFI isolated from normal 
human serum), the selective elevation of one of at least 
two CFI moities is a distinct possibility dependent on 
the disease and its progress. 
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Heat inactivation (56°C for 60 minutes) of sarcoid 
sera results in significant enhancement of indicator cell 
migration, indicating that CFI activity can be destroyed 
by heat (Table II). This suggests that CFI may have 
enzymatic-like action. 
Belcher, Carney and Nankervis described a heat stable 
(56°C for 30 minutes) factor in sarcoid serum which could 
diminish the response of normal lymphocytes to phytohe¬ 
magglutinin (5). Mangi, Dwyer and Kantor observed the 
same effect using sarcoid plasma even in combination with 
optimal levels of normal human plasma (64). The stability 
of these inhibitors separates them from CFI. 
There is also some similarity between CFI and 
anaphylatoxin inactivator (AI) as described by Bokisch 
et al (9). AI has carboxypeptidase B activity and 
largely accounts for the ability of normal human serum 
to rapidly destroy the kinins generated by kallikrein 
and the anaphylatoxin peptides C^a and C^a. 
Treatment of purified C3 and C5 with trypsin leads 
to the production of fragments with anaphylatoxin and 
chemotactic activity. Continued treatment abolishes the 
anaphylatoxin activity whereas there is no demonstrable 
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loss of chemotactic activity. This suggests non-identity 
of the two inactivators. There are other differences, 
but the final resolution of this question must await the 
availability of a highly purified preparation of CFI (6). 
Zymosan activation of most patient sera showed 
normal generation of complement dependent chemotactic 
factors via the alternate pathway (Tables III and IV). 
This indicated that low total complement levels in vivo 
are probably not a complication of sarcoidosis and that 
chemotactic activity which is generated in human serum 
by complement-activating substances is resistant to the 
effects of inactivators naturally present in serum (6). 
As shown in Tables I and II there is a low level of CFI 
in normal human sera. Perhaps these low levels are not 
sufficient to inactivate the large quantities of 
complement-derived chemotactic factors which are 
generated. Deficiencies in the complement cascade 
prior to would not be detected by this method. 
An attempt to determine the mode of action of the 
CFI either cell-directed or by directly inactivating the 
chemotactic factor, was inconclusive. Cell directed 
mediation could not be shown with the test method used. 
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Unexpectedly, some sarcoid sera produced actual enhance¬ 
ment of migration when incubated with the indicator cells 
at a 10% concentration. Similarly, unexplained enhance¬ 
ment was also noted using a leukocyte migration test in a 
study of sarcoidosis, normal controls and a variety of 
other disease states by Becker et al (3). The results 
of this investigation are so varied as to preclude any 
attempt at interpretation. However, techniques for cell- 
directed mediators seem to have some inherent problems. 
A cell-directed mediator may be irreversibly bound to 
cells and resist initial washing and, thus, remain 
refractile to correction. Conversely, if the mediator 
is lightly bound, it could be removed in the final wash 
before assaying. 
Berenberg et al incubated a concentrated CFI pre¬ 
paration in varying amounts with either the chemotactic 
factors or the indicator cells. As little as 10 micro¬ 
liters of the CFI preparation produced significant 
migration inhibition when mixed with the chemotactic 
factors, whereas at least 50 microliters mixed with 
indicator cells were needed to cause some decrease in 
migration. These results point to direct action on the 
71 
factors and not on the cells (6). 
A number of miscellaneous sera were tested for CFI 
activity using bacterial factor as the chemoattractant 
with the expected results. 
Sera from cirrhotic patients showed elevated levels 
of CFI which could be heat inactivated. Sera from 
Hodgkin's patients also exhibited elevated levels of CFI. 
Sera from cancer patients had mixed results. Special 
attention was given to sera from patients with neoplasia 
of the lung which could be comparable to sarcoidosis 
according to site. Generally low levels of CFI were 
found in these sera. 
Pooled sera from normal prenatal patients and sera 
from trauma victims with one exception gave normal results 
as expected. The one abnormal result in the group of 
hospitalized accident victims might well have had an 
underlying pathological condition unknown at the time of 
admittance. 
Sera from pregnant women were expected to show low 
(normal) levels of CFI because patients with sarcoidosis 
who become pregnant experience a clearing of disease 
manifestations with subsequent recurrence post partum. 
72 
Increased production of adrenal steroids in the second and 
third trimesters of pregnancy are thought to be responsible 
for this phenomenon (65, 78). 
The chemotaxis assay can be used easily and effectively 
to screen serum for chemotactic factor inactivator. Sera 
from healthy persons normally contain small amounts of the 
inactivator. Certain pathological conditions, such as 
sarcoidosis, Hodgkin's disease, and cirrhosis are 
associated with elevated serum levels of CFI. Sera from 
patients with sarcoidosis show an average 507. migration 
inhibition in the assay using normal serum as a base-line 
control. Sera from patients with other diseases have 
exhibited elevated ranges which indicate that the assay 
could be used diagnostically. Elevated levels of CFI 
discovered in apparently healthy individuals by a 
screening assay could indicate an incipient health 
problem. The standardized chemotaxis assay for CFI 
would be a valuable laboratory aid especially as more 
disease states are being investigated to determine 
characteristic levels of CFI. 
APPENDIXES 
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APPENDIX A 
Staging of Sarcoidosis 
Stage 0 - chest x-ray normal 
Stage I - hilar adenopathy with or without paratracheal 
node involvement, but without infiltrative 
disease 
Stage II - hilar adenopathy and parenchymal lesions 
with pulmonary infiltrates 
Stage III - parenchymal lesions with pulmonary fibrosis 
with or without hilar changes 
Stage IV - x-ray findings of previous stages disappeared, 
the x-ray now being normal 
(Mangi, R.J. , Dwyer, J.M., Gee, B., & Kantor, F.S.: 
Clin. exp. Immunology 18; 507, 1974, and Hedfors, E., 
Holm, G. , & Pettersson, D.: Clin. exp. Immunology 17; 
220, 1974.) 
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APPENDIX B 
Diagnostic Criteria 
"The criteria for the diagnosis of sarcoidosis were 
defined by a Subcommittee of the National Research Council 
in October, 1956. 
Sarcoidosis is a systemic disease, or group of 
diseases, of undetermined etiology and pathogenesis. 
Histologically, it is marked by the presence of epitheliod- 
cell tubercles, showing little or no necrosis. Varying 
types of inclusions in giant cells may be present but are 
not pathognomonic. A similar histological picture may be 
found in certain other diseases, especially in infectious 
granulomas and in beryllium poisoning. Clinically, the 
disease most commonly involves lymph nodes, lungs, skin, 
eyes, liver, spleen, and phalangeal bones. The course 
is usually chronic and constitutional symptoms vary 
markedly. More specific symptoms, when present relate 
to tissues and organs involved. 
The intracutaneous tuberculin test is frequently 
negative, but a positive test does not controvert the 
diagnosis. Hyperglobulinemia and leucopenia are common 
and hypercalcemia, hypercalciuria, elevated alkaline 
phosphatase, and eosinophilia are variable but sometimes 
significant features of sarcoidosis. 
The diagnosis of sarcoidosis is based upon the above 
clinical features associated with a compatible histological 
picture, provided beryllium poisoning and known infectious 
processes can be excluded. 
Spontaneous clinical recovery, with or without 
recognizable fibrosis, may result, or sarcoidosis may 
persist for years with varying functional alteration of 
the tissues or organs involved, or the disease may follow 
a progressive course ending fatally." 
(Ann. Intern. Med. Cummings Vol. 50, 1959, pp 883-884) 
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APPENDIX C 
The Ouchterlony Test 
Double Diffusion - Double Dimension 
Specific antibodies and antigens which are introduced 
into different regions of an agar gel diffuse freely toward 
each other and form visible opaque bands of precipitate at 
the junction of their diffusion fronts. 
To perform the double diffusion - double dimension 
test, a number of wells are cut into agar on a flat surface. 
The wells are filled with appropriate solutions of antigens 
and antiserum, covered to prevent evaporation and observed 
periodically for several days. When the antibodies meet 
their corresponding antigen, a band of precipitation appears. 
Purified preparations of C3 fragments were tested for 
specificity using a C3 antiserum preparation. A sharp 
band of precipitation between the C3 well and the anti-C3 
well indicated a relatively specific C3 preparation. 
Anti-C^ was included as a control. 
Well 1. anti-C3» well 2. C3. well 3. anti-C5 
Sample Ouchterlony Test 
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